Overview

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

Status:
Recruiting
Trial end date:
2024-02-14
Target enrollment:
Participant gender:
Summary
This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability over a 12-week double-blind period.
Phase:
Phase 2
Details
Lead Sponsor:
Celgene